|
NAPEPLD expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.47960000029812E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.27509999994879E-06 |
| Normal-vs-Stage2 |
2.451900E-02 |
| Normal-vs-Stage3 |
1.67549999985361E-07 |
| Normal-vs-Stage4 |
8.04659999964485E-07 |
| Stage1-vs-Stage2 |
3.473000E-01 |
| Stage1-vs-Stage3 |
1.305040E-01 |
| Stage1-vs-Stage4 |
5.683800E-02 |
| Stage2-vs-Stage3 |
8.368200E-02 |
| Stage2-vs-Stage4 |
3.429600E-02 |
| Stage3-vs-Stage4 |
4.561800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.29010000460283E-08 |
| Normal-vs-AfricanAmerican |
4.795100E-04 |
| Normal-vs-Asian |
1.549840E-02 |
| Caucasian-vs-AfricanAmerican |
5.313600E-01 |
| Caucasian-vs-Asian |
5.851600E-02 |
| AfricanAmerican-vs-Asian |
1.028180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.44509999977905E-07 |
| Normal-vs-Female |
2.92120000000562E-06 |
| Male-vs-Female |
4.716300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.92756999999322E-05 |
| Normal-vs-Age(41-60Yrs) |
1.98375000000084E-05 |
| Normal-vs-Age(61-80Yrs) |
8.44630000385038E-08 |
| Normal-vs-Age(81-100Yrs) |
1.158530E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.561800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.354050E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.004990E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.083800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.626300E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.162400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.818300E-03 |
| Classical-VS-Follicular |
6.193400E-01 |
| Classical-VS-Other |
3.076200E-01 |
| Classical-VS-Normal |
4.7222000000291E-06 |
| Tall-VS-Follicular |
3.784200E-02 |
| Tall-VS-Other |
7.832600E-01 |
| Tall-VS-Normal |
2.28949999958594E-07 |
| Follicular-VS-Other |
4.823600E-01 |
| Follicular-VS-Normal |
2.971300E-04 |
| Other-VS-Normal |
1.709690E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.83455999999138E-05 |
| Normal-vs-N1 |
6.196200E-04 |
| N0-vs-N1 |
9.345200E-01 |
|
|
